Medipharm Labs Corp T.LABS

Alternate Symbol(s): MEDIF

Healthcare Cannabis

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.

TSX:LABS - Post by User

Medipharm Labs Corp > LABS

<< Previous

Bullboard Posts

Next >>

Comment by Lemoyneon Mar 13, 2024 10:18pm

109 Views

Post# 35931822

RE:RE:LABS

There was no such teaser. Their guidance was as such,

MD&A Q1 2023:positive EBITDA and cash flow by first half 2024

MD&A Q2 2023: they removed any guidance because of uncertainty surrounding VIVO integration and restructuring costs taking more time and cash than anticipated.

MD&A Q3 2023: they guided for positive EBITDA and cashflow "in 2024"

your hopes for Q1 20m revs are going to put you in a world of hurt and disappointment most probably. the lack of a clear time line and potential postponement realistically puts positive cash flow in second half of 2024.

There could be a surprise, because of brazilian revs, but I wouldn't bet on it.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec